Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer
Author:
Publisher
Elsevier BV
Subject
Urology,Oncology
Reference29 articles.
1. Cancer incidence and incidence rates in Japan in 2005: Based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project;Matsuda;Jpn J Clin Oncol,2011
2. Recent advances in understanding hormonal therapy resistant prostate cancer;Donkena;Curr Cancer Drug Targets,2010
3. Beltran H, Beer TM, Carducci MA, et al. New therapies for castration-resistant prostate cancer: Efficacy and safety. Eur Urol in press.
4. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004
5. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis;Frontiers in Oncology;2023-12-15
2. Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel;Journal of Urologic Oncology;2023-11-30
3. Nadir prostate-specific antigen as a prognostic factor of 10-year cancer-specific survival of prostate cancer patients with bone metastases;Formosan Journal of Surgery;2022
4. Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells;Anticancer Research;2021-07-19
5. AN INDIAN PROSPECTIVE STUDY OF DOCETAXEL THERAPY IN CRPC: CAN PRETREATMENT FACTORS PREDICT THE RESPONSE;INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH;2021-05-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3